Enzyme Linked Immunosorbent Assay (ELISA) Market Size, 2033

Technological Advancements in Automated and High-Sensitivity Diagnostic Testing to Drive Global Enzyme Linked Immunosorbent Assay (ELISA) Market to USD 3,476.00 Mn by 2033 at 5.1% CAGR – Coherent Market Insights

Global Enzyme Linked Immunosorbent Assay (ELISA) Market – Driver

Expanding Infectious-Disease Testing and Biopharmaceutical Quality Control

The Global Enzyme-Linked Immunosorbent Assay (ELISA) Market is driven by the growing requirement for sensitive and scalable antigen and antibody detection in infectious-disease surveillance, clinical diagnosis, vaccine research, and biologics quality testing. This increases recurring demand for ELISA kits, antibodies, substrates, reagents, microplate readers, and automated laboratory systems.

For instance, in January 2026, Bangladesh confirmed a Nipah virus infection using PCR and ELISA, while exposed symptomatic contacts were tested through anti-Nipah IgM ELISA. WHO also identifies ELISA-based antibody detection as one of the principal laboratory methods for Nipah diagnosis. Additionally, in July 2026, the U.S. FDA approved Sanofi’s replacement of three mouse immunogenicity assays with antigenicity ELISA methods for ADACEL vaccine quality testing, demonstrating ELISA’s expanding adoption in regulated vaccine manufacturing. (Source: WHO; U.S.FDA)

Global Enzyme Linked Immunosorbent Assay (ELISA) Market – Opportunity

Commercialization of Portable, Smartphone-Based and AI-Enabled ELISA Systems

The development of portable, automated and smartphone-integrated ELISA platforms presents a significant opportunity for the Global Enzyme-Linked Immunosorbent Assay Market. These systems can reduce dependence on expensive laboratory readers and expand ELISA testing across point-of-care facilities, mobile laboratories and resource-limited regions. Integration with artificial intelligence can also improve result interpretation, analytical accuracy and high-throughput screening. For instance, in April 2026, an ACS Omega study demonstrated a smartphone-based colorimetric ELISA reader integrated with an XGBoost machine-learning model. The system achieved R² values above 0.999 across four human cancer cell lines and reduced analytical error by more than 98%, supporting its potential for decentralized diagnostics and high-throughput screening. (Source: NCBI)

Global Enzyme Linked Immunosorbent Assay (ELISA) Market – Trends

Growing adoption of digital and ultrasensitive ELISA: Digital ELISA platforms are gaining prominence for detecting extremely low concentrations of proteins and disease biomarkers that conventional assays may not reliably quantify. In April 2026, researchers developed a hypersensitive digital ELISA system that specifically detected hepatitis B core antigen in serum and plasma samples.
Increasing automation and high-throughput assay processing: Laboratories are increasingly adopting automated liquid handling, plate washing and miniaturized ELISA workflows to reduce manual errors and accelerate sample processing. A 2026 Merck study demonstrated automated ELISA development in a 384-well format, improving throughput, accuracy and reliability in monoclonal-antibody potency testing. (Source: NCBI)
Integration of artificial intelligence and smartphone-based readers: Smartphone imaging and machine-learning algorithms are transforming colorimetric ELISA into a portable and cost-effective diagnostic platform. In April 2026, an XGBoost-enabled smartphone ELISA reader achieved R² values above 0.999 and reduced analytical error by more than 98%, supporting decentralized testing and high-throughput screening.
Expansion of multiplex ELISA and protein-biomarker panels: Demand is increasing for platforms capable of measuring multiple biomarkers from a single sample, particularly in oncology, neurology, immunology and drug development. In May 2026, researchers validated a 15-plex proximity-barcoded digital immunoassay in human plasma, achieving low-femtomolar sensitivity and high measurement accuracy.
Rising adoption in on-site food-safety testing: ELISA applications are expanding beyond clinical diagnostics into food contamination, agricultural testing and veterinary surveillance. A 2026 study introduced a 4D-printed ELISA needle panel for on-site chloramphenicol detection, validating the method across seafood, meat, honey and milk samples with a detection limit of 2.5 pg/mL.
Increasing use of ELISA in regulated biopharmaceutical quality control: Pharmaceutical and vaccine manufacturers are increasingly using validated ELISA methods for antigenicity, potency and product-quality testing. In July 2026, the U.S. FDA approved the replacement of three mouse immunogenicity assays with antigenicity ELISA methods for Sanofi’s ADACEL vaccine, supporting animal-reduction initiatives and standardized quality testing. (Source: U.S.FDA)

Global Enzyme Linked Immunosorbent Assay (ELISA) Market, by Method (Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry & Transplantation), by Technology (Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,456.60 Million in 2026 and is expected to exhibit a CAGR of 5.1% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Increasing product approvals by regulatory authorities and government organizations is expected to drive market growth over the forecast period. For instance, On June, 22, 2022, Pictor, an in vitro diagnostics company received The Conformitè Europëenne (CE) marking for its PictArray SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) antibody test to enable personalized Covid-19 assessment. The PictArray SARS-CoV-2 IgG ELISA kit has been designed to separately identify antibodies from Covid-19 infection and vaccination.

Global Enzyme Linked Immunosorbent Assay (ELISA) Market: Key Developments

In July 2026, Hutton Scientific Services, the commercial arm of The James Hutton Institute, launched a commercial potato virus testing service for the United Kingdom seed potato campaign. The service provides ELISA and rapid real-time PCR testing for Potato Virus Y and Potato Leafroll Virus. This development demonstrates the expanding adoption of ELISA-based diagnostics in agricultural disease surveillance, seed certification, crop management, and plant-health testing.
In April 2026, Abcam, a Danaher company, launched SimpleStep Ignite ELISA, a next-generation chemiluminescent immunoassay platform. The solution delivers results within 55 minutes, offers up to 50 times greater sensitivity, and provides a measuring range up to 35 times wider than conventional colorimetric ELISA. The platform supports faster biomarker quantification across serum, plasma, urine, and cerebrospinal fluid samples. (Source: Abcam)
In June 2026, Cavidi launched the Exazym StreptaClick Primer, a ready-to-use reagent designed to integrate BOLD signal amplification into conventional sandwich ELISA workflows. The product eliminates the need for offline antibody-conjugation procedures and works with biotinylated detector antibodies. Performance testing demonstrated sensitivity improvements for low-abundance cytokines, strengthening the product’s potential in biomarker research and high-sensitivity immunoassay development. (Source: Cavidi)
In May 2026, MyBioSource announced the availability of an expanded collection of ready-to-use and customizable ELISA kits for researchers globally. The portfolio covers numerous species, biological samples, and research targets, enabling laboratories to select kits according to specific experimental requirements. The development represents a commercial portfolio expansion that could improve accessibility to ELISA products across biomedical, pharmaceutical, veterinary, and life-science research applications.
In July 2026, Hutton Scientific Services launched a commercial potato virus testing service for the United Kingdom’s seed potato industry. The service uses ELISA and rapid real-time PCR testing to detect Potato Virus Y and Potato Leafroll Virus. The launch highlights the expanding application of ELISA technology beyond clinical diagnostics into agricultural disease surveillance, seed certification, crop-health management, and commercial plant-pathology testing. (Source: Hutton Scientific Services)

Browse 34 Market Data Tables and 38 Figures spread through 156 Pages and in-depth TOC on “Global Enzyme Linked Immunosorbent Assay (ELISA) Market”- Forecast to 2030, Global Enzyme Linked Immunosorbent Assay (ELISA) Market, by Method (Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry & Transplantation), By Technology (Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in Enzyme Linked Immunosorbent Assay (ELISA) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/enzyme-linked-immunosorbent-assay-market-1505

Moreover, increasing product launches by market players are expected to drive market growth during the forecast period. For instance, On September 3, 2020, Leinco Technologies, a biotechnology company and ADMA Biologics, Inc. a biopharmaceutical company had announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in plasma. ImmunoRank is intended for use as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2.

Key Takeaways of the Global Enzyme Linked Immunosorbent Assay (ELISA) Market

Global Enzyme Linked Immunosorbent Assay (ELISA) market is expected to exhibit a CAGR of 5.1% during the forecast period due to increasing research and development by research institutes for developing ELISA kit. For instance, on December 21, 2021, researchers from the Primate Animal Study Center (PASC) of the Institute for Research and Community Service (IoRCS) IPB University, Indonesia succeeded in developing an ELISA (Enzyme-Linked Immunosorbent Assay)-based COVID-19 antibody kit. The antibody kit was known as ‘IPB ELISA Kit, COVID-19 Antibody’.
Among Technology, the colorimetric, segment holds a dominant position with share of 57.8%, because it provides a simple, cost-effective, reliable, and widely standardized method for detecting and quantifying antibodies, antigens, proteins, hormones, and disease biomarkers. For instance, in April 2026, ACS Omega published a smartphone-based colorimetric ELISA reader enhanced with XGBoost, achieving R² above 0.999 across four cancer cell lines and reducing RMSE by over 98%, demonstrating colorimetric ELISA’s portability, accuracy, and suitability for decentralized diagnostics.
Among regions, North America is expected to hold the dominant position in market with share of 43%, owing to product launches by market players in the region. For instance, In October, 2020, VEO Diagnostics, a manufacturing company of medical diagnostic products had announced the launch and sole distribution rights in the U. S. to the ACCEL ELISA COVID-19 kit, a serological microplate-based enzyme linked Immunosorbent assay (ELISA) for the qualitative detection of total antibodies (including IgG, IgM, and IgA) to SARS-CoV-2 in human serum. ACCEL ELISA is intended for use as an aid in identifying individuals with an adaptive immune response to SARS CoV-2.
Major players operating in the global Enzyme Linked Immunosorbent Assay (ELISA) market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., R&D Systems, Creative Diagnostics, Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.